HOME > News > Event Recaps > 2025.05.26 Glac Biotech Showcases at Vitafoods Europe 2025

News

2025.05.26 Glac Biotech Showcases at Vitafoods Europe 2025

Share to

Comprehensive Presentation of Probiotics × Postbiotics Research, with Totipro® PE0301 in the Spotlight
From May 20–22, 2025, Glac Biotech participated in Vitafoods Europe 2025 in Barcelona, Spain — one of the most influential trade shows for the global food and nutrition industry.
At the exhibition, Glac Biotech highlighted its latest scientific achievements in the PRONULIFE® functional probiotics and Totipro® postbiotics series, drawing strong interest from buyers and partners across Europe, the Americas, and Asia. Among the highlights was Totipro® PE0301, which had recently been shortlisted for the NutraIngredients Awards in the Microbiome Modulation category. Its dual-action applications for oral and gastric health attracted significant industry attention and discussion.

Totipro® PE0301 Highlights

  • Dual Protection: Supports both oral microbiota and gastric health by inhibiting oral pathogens and Helicobacter pylori, while promoting beneficial bacterial stability.
  • Versatile Applications: Suitable for multiple product formats, including capsules, powders, and beverages, offering greater flexibility in formulation.
  • Scientific Validation: Backed by the Totipro® series’ strong foundation of patents and clinical research, gaining recognition in both European and Asian markets.

Engagement and Global Collaboration

Throughout the three-day exhibition, Glac Biotech’s booth welcomed a steady flow of international visitors. Key discussions focused on:
  • The potential of Totipro® postbiotics in the European functional food market.
  • Expansion opportunities for the PRONULIFE® probiotic portfolio in gut health, immunity, and women’s health segments.
  • The advantages of PRIMETEK® one-stop OEM services, offering integrated solutions from strain development and raw material production to finished product manufacturing.

Looking Ahead

Through this exhibition, Glac Biotech not only demonstrated its comprehensive probiotic × postbiotic portfolio, but also strengthened connections with partners across Europe and global markets. Moving forward, the company will continue to place scientific validation at its core, advancing clinical research and patent applications, and working hand-in-hand with international brands to new opportunities in the health food industry.

Media Coverage (Extended Reading)

Taiwan News — May 7, 2025 (English)
“GLAC Biotech shortlisted for award at Spain’s Vitafoods Exhibition”
     
 
Previous Back to list Next
Back
TOP